Anixa Biosciences (ANIX) director purchases 10,000 company shares

Rhea-AI Filing Summary

Anixa Biosciences director Arnold M. Baskies reported buying additional company stock. On January 28, 2026, he purchased 10,000 shares of Anixa Biosciences common stock at $3.04 per share. Following this open-market purchase, he directly owns 135,000 shares of the company’s common stock.

Insider Trade Summary

Net Buyer: 10,000 shares ($30,400)

Net Buy 1 txn

Insider Baskies Arnold M

Role Director

Bought 10,000 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$3.04	$30K

Holdings After Transaction: Common Stock — 135,000 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baskies Arnold M

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		P		10,000	A	$3.04	135,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Arnold M. Baskies	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Anixa Biosciences (ANIX) report in this Form 4?

Anixa Biosciences reported that director Arnold M. Baskies purchased 10,000 shares of its common stock. The transaction occurred on January 28, 2026 and was coded as a P transaction, indicating an open-market or private purchase of non-derivative shares.

How many Anixa Biosciences (ANIX) shares did the director buy and at what price?

Director Arnold M. Baskies bought 10,000 shares of Anixa Biosciences common stock at a price of $3.04 per share. This was a single non-derivative transaction recorded on January 28, 2026 under transaction code P for a purchase.

How many Anixa Biosciences (ANIX) shares does Arnold M. Baskies own after this trade?

After the reported transaction, Arnold M. Baskies beneficially owns 135,000 shares of Anixa Biosciences common stock. The Form 4 shows these shares as held under direct ownership, meaning they are not reported as indirectly owned through another entity or person.

Is the Anixa Biosciences (ANIX) insider transaction a purchase or a sale?

The transaction is a purchase. The Form 4 lists transaction code P, which denotes an open-market or private purchase of non-derivative securities. Director Arnold M. Baskies acquired 10,000 shares of Anixa Biosciences common stock on January 28, 2026.

Does the Anixa Biosciences (ANIX) director hold his shares directly or indirectly?

The Form 4 shows that 135,000 shares of Anixa Biosciences common stock are owned with a status of Direct (D). No nature of indirect beneficial ownership is listed, indicating the reported holdings are directly attributed to Arnold M. Baskies himself.

Are there any derivative securities reported for Anixa Biosciences (ANIX) in this Form 4?

No derivative securities are reported in this filing. The section for derivative securities lists no options, warrants, or other derivatives. The only disclosed activity is a non-derivative purchase of 10,000 common shares by director Arnold M. Baskies on January 28, 2026.